

28 November 2024

**N4 Pharma plc
("N4 Pharma" or the "Company")**

Grant of Options

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, announces that, on 27 November 2024, the Board granted 15 million options (the "Options") over ordinary shares of 0.4p each in the Company to certain directors of N4 Pharma as follows:

<i>Director</i>	<i>Number of options granted</i>
Nigel Theobald (Chief Executive Officer)	6,000,000
Michael Palfreyman (Non-Executive Director)	3,000,000
Dr Chris Britten (Non-Executive Chairman)	3,000,000
Luke Cairns (Executive Director)	3,000,000

The Options have an exercise price of 0.75p and vest in three equal tranches on the first, second and third anniversaries from the date of grant. The Options have a term of ten years from the date of grant.

The FCA notifications, made in accordance with the requirements of the Market Abuse Regulation, are appended below.

For more information please contact:

N4 Pharma plc

Nigel Theobald, CEO
Luke Cairns, Executive Director

Via N4 Pharma Investor Hub

Engage with us directly at N4 Pharma Investor Hub

Sign up at investors.n4pharma.com

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited

Joint Broker
Andy Thacker
James Pope

Tel: +44(0)20 3657 0050

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.

N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Nigel Theobold					
2	Reason for the notification						
a)	Position/status	Chief Executive Officer					
b)	Initial notification /Amendment	Initial notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	N4 Pharma plc					
b)	LEI	213800I841D2RKMFK955					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary Shares of 0.4p each Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32					
b)	Nature of the transaction	Issue of options over ordinary shares of 0.4p each					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>0.75p exercise price</td><td>6,000,000</td></tr></table>	Price(s)	Volume(s)	0.75p exercise price	6,000,000	
Price(s)	Volume(s)						
0.75p exercise price	6,000,000						
d)	Aggregated information - Aggregated volume - Price	n/a					
e)	Date of the transaction	27 November 2024					
f)	Place of the transaction	Outside a trading venue					

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Michael Palfreyman
2	Reason for the notification	
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	N4 Pharma plc
b)	LEI	213800I841D2RKMFK955
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Options over Ordinary Shares of 0.4p each
	Identification code	Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32

b)	Nature of the transaction	Issue of options over ordinary shares of 0.4p each		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		0.75p exercise price	3,000,000	
d)	Aggregated information - Aggregated volume - Price	n/a		
e)	Date of the transaction	27 November 2024		
f)	Place of the transaction	Outside a trading venue		

1	Details of the person discharging managerial responsibilities / person closely associated			
a)	Name	Dr Chris Britten		
2	Reason for the notification			
a)	Position/status	Non-Executive Chairman		
b)	Initial notification /Amendment	Initial notification		
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	N4 Pharma plc		
b)	LEI	213800I841D2RKMFK955		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary Shares of 0.4p each Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32		
b)	Nature of the transaction	Issue of options over ordinary shares of 0.4p each		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		0.75p exercise price	3,000,000	
d)	Aggregated information - Aggregated volume - Price	n/a		
e)	Date of the transaction	27 November 2024		
f)	Place of the transaction	Outside a trading venue		

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Luke Cairns
2	Reason for the notification	
a)	Position/status	Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	N4 Pharma plc

b)	LEI	2138001841D2RKMFK955		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary Shares of 0.4p each Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32		
b)	Nature of the transaction	Issue of options over ordinary shares of 0.4p each		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		0.75p exercise price	3,000,000	
d)	Aggregated information - Aggregated volume - Price	n/a		
e)	Date of the transaction	27 November 2024		
f)	Place of the transaction	Outside a trading venue		

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEAEFXAEDLFAA